Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 11/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 2/20 | 0.34 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | INSR | P06213 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14899105 | 0.93 | ACVRL1 (0.49) | ACVRL1MERTKPIK3CD | |
| SCHEMBL14899089 | 0.88 | ACVRL1 (0.44) | ACVRL1MERTKTNK2MET | |
| SCHEMBL14312666 | 0.84 | ACVRL1 (0.45) | ACVRL1MERTKTNK2IGF1RMET | |
| SCHEMBL14899086 | 0.84 | ACVRL1 (0.37) | ACVRL1MERTKTNK2RETKDR | |
| SCHEMBL14312731 | 0.84 | ACVRL1 (0.46) | ACVRL1MERTKTNK2IGF1RMET | |
| SCHEMBL14327041 | 0.83 | ACVRL1 (0.49) | ACVRL1MERTKTNK2PIK3CDIGF1R | |
| SCHEMBL16508302 | 0.82 | ACVRL1 (0.40) | ACVRL1MERTKTNK2IGF1RKDR | |
| SCHEMBL14312351 | 0.82 | ACVRL1 (0.40) | ACVRL1MERTKTNK2IGF1RKDR | |
| SCHEMBL14899104 | 0.82 | ACVRL1 (0.40) | ACVRL1MERTK | |
| SCHEMBL14313449 | 0.82 | PIK3CD (0.43) | ACVRL1TNK2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431695-B2 | Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-30 | — | — | US | disclosed |